Login to Your Account



PHARMA FOCUS

Generic challenger surfaces in Actavis for Vivus obesity drug Qsymia

By Randy Osborne
Staff Writer

Friday, May 9, 2014
The battle for obesity market share became unsurprisingly more complicated with the notice by Actavis plc that it has filed an abbreviated new drug application (ANDA) for all strengths of one of the market players: Vivus Inc.'s Qsymia (phentermine/topiramate).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription